Source: Annual Congress 2002 - Mesothelioma and malignant pleural effusion
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Metintas, S. Metintas, G. Ak, S. Erginel, I. Ucgun, F. Alatas (Eskisehir, Turkey). Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients. Eur Respir J 2002; 20: Suppl. 38, 1742

Member's Comments

No comment yet.

Related content which might interest you: Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Clinical characteristics, treatment and survival outcomes in malignant mesothelioma Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Predicting survival in malignant mesothelioma Source: Eur Respir J 2011; 38: 1420-1424 Year: 2011 Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Malignant pleural mesothelioma clinical aspects and survival in 93 cases Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy. Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications Year: 2020 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Extrapleural pneumonectomy versus pleurectomy/decortication in malignant pleural mesothelioma: an updated meta-analysis of survival endpoints Source: International Congress 2019 – All aspects of general thoracic surgery Year: 2019 Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011 Evaluation of chemotherapy response determined by volumetric method in malignant pleural mesothelioma and its effect on determination to survival Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases Year: 2009